METHOD OF TREATING PATIENTS WITH PRIMARY SKIN MELANOMA Russian patent published in 2012 - IPC A61N5/67 A61K31/409 A61P35/00 

FIELD: medicine.

SUBSTANCE: photosentitiser photosense 0.3-0.4 mg/kg is administered intravenously into a patient. Then 2-3 hours later, a tumour and surrounding skin are exposed to a circular field of laser tele-irradiation at the distance of min. 3 cm at wave length 670 nm, single light dose min. W_s 50 J/cm² and power density P_s 40÷50 mWt/cm². Thereafter, a tumour diameter is exposed to the circular field at single light dose W_s 100÷200 J/cm² and power density P_s 100÷200 mWt/cm². After a pause of 24 hours, irradiation of the same mode is added with contact irradiation generated from 2-3 positions and covering the tumour and border skin at light dose W 100 J and light guide output power P 200÷250 mWt in each position.

EFFECT: method enables the effective therapeutic management of the patients with stages 1-2a-3a primary skin melanoma, provides avoiding surgical interventions requiring general anaesthesia, makes it possible to treat the patients with manifested cardiac, pulmonary and other comorbidities if observing contraindications for surgical management and general anaesthesia, allows outpatient care, reduces length of treatment and medical rehabilitation, minimises post-treatment complications.

2 ex